Generic-Drug Failures Spur Concern As FDA Steps Up Action
3/3/2014 7:33:13 AM
U.S. regulators are mobilizing to shore up confidence in America’s generic-drug supply as alarm grows over the quality of products made in India, and the head of the largest U.S.-based maker of the medicines predicted more trouble lies ahead. “It’ll get worse before it gets better,” said Mylan (MYL) Inc. Chief Executive Officer Heather Bresch, whose company has half of its more than 20,000 employees in India. As regulators boost inspections there, consumers will see “more market disruption, more companies being shut down, more bans on facilities,” she said in an interview.
Help employers find you! Check out all the jobs and post your resume.
comments powered by